
M. Mengel\(^a,b,^*\), B. Sis\(^a,b\), M. Haas\(^c\), R. B. Colvin\(^d\), P. F. Halloran\(^b\), L. C. Racusen\(^b\), K. Solez\(^a\), L. Cendales\(^f\), A. J. Demetris\(^g\), C. B. Drachenberg\(^h\), C. F. Farver\(^i\), E. R. Rodriguez\(^i\), W. D. Wallace\(^l\), D. Glotz\(^k\), and as the Banff meeting report writing committee

\(^a\)Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Canada
\(^b\)Department of Medicine, Alberta Transplant Applied Genomics Centre, Division of Nephrology & Immunology, University of Alberta, Edmonton, Canada
\(^c\)Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA
\(^d\)Department of Pathology, Harvard Medical School and Massachusetts General Hospital, Boston, MA
\(^e\)Department of Pathology, Johns Hopkins University, Baltimore, MD
\(^f\)Emory Transplant Center, Emory University School of Medicine and Atlanta Veterans Affairs Medical Center, Atlanta, GA
\(^g\)Division of Transplantation Pathology, Department of Pathology, University of Pittsburgh, Pittsburgh, PA
\(^h\)Department of Pathology, University of Maryland, Baltimore, MD
\(^i\)Department of Anatomic Pathology, Cleveland Clinic, Cleveland, OH
\(^l\)Department of Laboratory Medicine and Pathology, University of California, Los Angeles, CA
\(^k\)Department of Nephrology, Hospital Saint-Louis, Paris, France

Abstract

The 11th Banff meeting was held in Paris, France, from June 5 to 10, 2011, with a focus on refining diagnostic criteria for antibody-mediated rejection (ABMR). The major outcome was the acknowledgment of C4d-negative ABMR in kidney transplants. Diagnostic criteria for ABMR have also been revisited in other types of transplants. It was recognized that ABMR is associated with heterogeneous phenotypes even within the same type of transplant. This highlights the necessity of further refining the respective diagnostic criteria, and is of particular significance for the design of randomized clinical trials. A reliable phenotyping will allow for definition of robust end-points. To address this unmet need and to allow for an evidence-based refinement of the Banff classification, Banff Working Groups presented multicenter data regarding the reproducibility of features relevant to the diagnosis of ABMR. However, the consensus was that more data are needed for robust definition.
necessary and further Banff Working Group activities were initiated. A new Banff working group was created to define diagnostic criteria for ABMR in kidneys independent of C4d. Results are expected to be presented at the 12th Banff meeting to be held in 2013 in Brazil. No change to the Banff classification occurred in 2011.

Keywords
Allograft rejection; allograft transplantation; antibody-mediated rejection; Banff classification

Introduction
The 11th Banff Conference on Allograft Pathology was held in Paris, France from June 5 to 10, 2011. A total of 288 transplant pathologists, clinicians, surgeons, immunologists and researchers from more than 30 countries discussed aspects relevant to the specific types of organ transplants. Furthermore, Banff Working Groups (BWGs) provided progress reports on activities conducted over the past 2 years. The major focus of discussions was antibody-mediated rejection (ABMR) in all types of organ transplants. The most relevant outcome in this regard was the recognition of C4d-negative ABMR in kidney allografts.

New Concepts in Antibody-Mediated Rejection
Assessing and managing the presensitized patient
The 11th Banff meeting started with a 1-day premeeting on the diagnostic and therapeutic challenges in presensitized patients. The presence of donor-specific antibodies (DSA) at or before transplantation is associated with an increased frequency of ABMR and inferior outcome. But not all antibodies detected by highly sensitive assays cause a phenotype in the allograft and not all antibody-mediated phenotypes inevitably cause accelerated allograft failure. Thus the need for reliable risk stratification was identified. Various approaches to address this unmet need were discussed: measuring mean fluorescence intensity levels of DSA (1,2), the calculated PRA to better assess the risk pretransplant (3), subtyping of IgG-anti-HLA antibodies (4) and identification of C1q-fixing donor-specific antibodies (5). However, there is yet no consensus on relevant thresholds for the various method platforms which are associated with various degrees of sensitivity and specificity. Numerous factors (e.g. treatment with therapeutic antibodies, data normalization) can interfere with the result from antibody testing, in particular for flow-based cross-matches (6,7). To mitigate the ongoing deficit in this area, collaborative standardization efforts are underway (8). However, at this stage the transplant community has to accept that all antibody assays have limitations, which need to be taken into account when test results are interpreted.

In kidney transplantation a large variety of desensitization protocols have been described, with IVIG used most frequently (9). Overall successful desensitization is associated with improved patient survival compared to long-term dialysis (10).

Most therapeutic tools for sensitized patients were transferred from other areas into transplantation. These include plasma exchange and drugs such as IVIG, rituximab, bortezomib and eculizumab. There is evidence that applying one of these modalities alone is less effective than the combination of several (11). Thus the need is for well-designed randomized clinical trials, in which combination therapies would be tested (12). It was emphasized at this meeting and at a recent FDA workshop (13) that the ability to correctly define antibody-mediated phenotypes in allografts is essential for adequately powering randomized clinical trials. Defining the ABMR phenotype including activity grading and chronicity staging is challenging and requires that the various aspects of ABMR are taken...
into account: the nature of the antibody, the significance of C4d, allograft pathology, allograft function and outcome. Two major phenotypes of ABMR were identified: phenotype 1—ABMR developing in the presensitized patient early posttransplantation and phenotype 2—ABMR after de novo DSA developing late posttransplantation, mostly in relation to noncompliance (14). Phenotype 2 represents a significant contributor to late renal allograft loss (14–17). Against this background the aim of a randomized clinical trial needs to be clearly defined. If it is the prevention of phenotype 1 ABMR in the presensitized patient, the diagnosis of ABMR would be the end-point. A trial involving phenotype 2 patients, the diagnosis of ABMR would be the entry point into the trial and the amelioration of the ABMR phenotype would be the end point. It was pointed out that in addition to antibody measurement, C4d staining and histopathology, molecular measurements (18,19) can help to grade and stage disease activity and progression.

**Diagnosis, grading and staging of antibody-mediated injury in kidney allografts**

The challenges in diagnosis, grading and staging of ABMR include the facts that morphological features are dependent on the time point in the course of the disease, and the dynamics of the disease course show significant individual variability. In this context it is important to note that the term “chronic” is not related to a certain time posttransplantation but indicates morphological changes of remodeling seen in the allograft due to antibody-mediated injury, e.g. double contours of glomerular basement membranes (GBM). The groups from Paris showed that in presensitized patients persistent subclinical microcirculation inflammation (MI = capillaritis and/or glomerulitis) leads to chronic microvascular remodeling (= transplant glomerulopathy and peritubular capillary basement membrane multilayering) (20,21). These cases were frequently C4d negative despite the presence of DSA and MI. The risk of progressing to chronic ABMR was also independent of C4d and primarily driven by the presence of DSA and MI. Furthermore, the same groups presented compelling data indicating that the progression of allograft arteriosclerosis in large arteries is associated with DSA and the diagnosis of ABMR, independently of other classical risk factors (aging, hypertension, diabetes) (22,23). Recent data show that Banff v1 and v2 lesions, i.e. intimal arteritis that is traditionally attributed to TCMR, have an association with ABMR (24). Preliminary data were presented by Anthony Chang and coworkers (University of Chicago) at the meeting indicating that immunophenotyping of intimal arteritis reveals significantly higher numbers of NK cells (CD56+) in the subendothelial infiltrate of v-lesions in the setting of ABMR compared to TCMR.

The significance of MI in sensitized patients under the influence of treatment was discussed in detail. Early biopsies from presensitized patients treated with eculizumab were diffusely C4d positive but did not show morphological signs of ABMR including lack of endothelial cell activation by electron microscopy (25). Early assessment by electron microscopy (e.g. <3 months post-Tx) in sensitized patients turned out to be very sensitive for the detection of endothelial injury (26), but the observed changes were not predictive of later development of TG in eculizumab-treated patients. The fact that complement component C5 as the target of eculizumab is downstream of C4d explains the diffuse positivity for C4d, while the lack of respective pathology suggests that eculizumab simultaneously protects the endothelium. However, some patients developed chronic ABMR with TG despite eculizumab. This highlights that complement inhibition alone does not prevent the development of chronic, antibody-mediated MI, and also illustrates limitations in the diagnostic reliability of C4d and DSA. This leaves morphology as crucial for diagnosis, staging and grading of ABMR with MI emerging as the most significant harbinger of later signs of chronic ABMR (27,28).

But the specificity of ABMR-associated histological lesions is limited as well. Glomerulitis can occur in TCMR and responds to steroid treatment (29). And there is still an ongoing debate about the exact percentage of cases with GBM double contours not attributable to
DSA. The numbers vary between 20% and 50% with some cases being attributable to thrombotic microangiopathy and/or hepatitis C (30). Thus the most important challenge currently faced by the Banff community lies in identifying clinically relevant thresholds and reproducible criteria for assessing antibody-mediated microcirculation injury in renal allografts.

Banff Working Group (BWG) activities

Banff Working Groups were established at the 2009 meeting with the aim of conducting multicenter trials to evaluate the clinical relevance, practical feasibility and reproducibility of potential evidence-based changes to the Banff classification (31). Preliminary results and current activity status of the BWGs are summarized in Table 1. Detailed reports from all BWG activities will be published separately.

Banff working lunch and online discussions on C4-negative ABMR

Significant limitations of C4d as a diagnostic marker for ABMR were identified. According to the current Banff classification only diffuse C4d staining by immunofluorescence on frozen sections or at least focal staining by immunoperoxidase on paraffin sections can be called ABMR (31). C4d-negative cases showing MI in the presence of DSA are termed suspicious for ABMR. It is evident that C4d is of limited sensitivity due to methodologic issues, but also due to real biological phenomena like noncomplement fixing antibodies, waxing and waning of C4d deposition or reduced capillary density. In addition, positive staining for C4d without MI or graft dysfunction can be observed in AB0-incompatible cases and patients treated with eculizumab. The existence of C4d-negative ABMR as a phenotype has been broadly accepted by the participants of a working lunch at the 11th Banff meeting. A new working group was established with the goal of defining and validating reproducible, relevant and clinically feasible diagnostic criteria for C4d-negative ABMR. In this regard, the detection of NK cells and endothelial activation may be helpful in identifying C4d-negative cases (18,19). It was acknowledged that it is crucial to prevent over-diagnosing ABMR since treatment is significant in terms of side effects and costs. To this end there remain important issues that need to be resolved before a diagnostic category of C4d-negative ABMR can be added to the Banff classification. These include:

1. Defining appropriate thresholds for microvascular injury and for DSA that provide an optimal balance of specificity and sensitivity for ABMR, noting that none of these morphologic changes are specific and that not all patients with DSA have ABMR.
2. Defining “C4d-negative”. There is some evidence that focal C4d is often (though less so than diffuse C4d) associated with DSA and microvascular injury (32).
3. Defining acute versus chronic/active ABMR.
4. Defining the significance of intimal arteritis (in the absence of necrosis) as histologic evidence for ABMR.

Novel insights from kidney allograft protocol biopsies

New findings emerged from studies of both early and late protocol biopsies of renal allografts.

1. MI (± C4d positivity) may be seen in early protocol biopsies, although this is most often observed in patients with some immunologic risk for sensitization. Nonetheless, this early subclinical injury does correlate with an increased risk for later development of TG in nonsensitized patients, just as it does in patients with pre-existing DSA.
2. The use of immunosuppressive regimens utilizing tacrolimus in lieu of cyclosporine with mycophenolate mofetil results in reduced levels of IFTA, interstitial inflammation in both scarred and nonscarred areas, and evidence of chronic microvascular injury during the first 4–5 years posttransplantation (33). However, the significance of some of these differences was lost at later time points, and there was no improvement in death-censored graft or patient survival. This may reflect chronic calcineurin inhibitor (CNI) nephrotoxicity. This assumption fueled a lively debate about the significance of CNI nephrotoxicity as a contributor to renal allograft deterioration, particularly against the background of recent data indicating that no specific morphological lesions for CNI nephrotoxicity exist (34). However, this issue will require more long-term data from trials using noninferior CNI-free immunosuppression protocols.

3. Molecular analysis of early (6 week) protocol biopsies provides evidence that mild subclinical TCMR has a molecular signature similar to that of injury-induced inflammation and is different from clinical overt TCMR in time-matched indication biopsies (35). Furthermore, early subclinical infiltrates were not associated with subsequent progression of IFTA, even when untreated. These findings suggest that very early protocol biopsies reflect prior injury and are of limited value in nonsensitized recipients for predicting the future course. In contrast, molecular studies of 1-year protocol biopsies showed expression of many profibrotic genes in both histologically normal biopsies and those showing IFTA without inflammation. However, a subset of 1-year protocol biopsies with IFTA+inflammation showed a different expression profile and was associated with progressive deterioration (36). This indicated that in later protocol biopsies a subgroup of patients with subclinically progressive injury exists which needs to be better understood.

4. Studies of urine and blood biomarkers have potential to identify recipients with subclinical TCMR, thus reducing the need for protocol biopsies. Analysis of urine metabolites identified differences in patients with and without subclinical TCMR, and normalization of the rejection spectral pattern associated with morphologic resolution of TCMR after treatment. Furthermore, renal graft recipients with operational tolerance have increased circulating numbers of specific memory B-cell populations (37). Notably, a subset of these patients did develop late graft dysfunction, sometimes with TG that may lead to graft loss; loss of these memory B cells from the blood may correlate with these negative outcomes.

In summary, an unselective, general application of protocol biopsies particularly early posttransplant, appears not justified. However, protocol biopsies provide the biggest return of investment in high-risk patients and in cases with a high prior probability for progressive lesions, e.g. early in presensitized patients.

New developments in other organ transplants

Liver allografts—The liver sessions included three interrelated topics: (1) biopsy findings in long-term immunosuppression management with a focus on defining histopathologic criteria for spontaneous operational tolerance (SOT); (2) role of ABMR and utility of C4d staining; (3) use of emerging technologies to augment histopathology. The first topic is the focus of a consensus document discussed at the 2009 and 2011 meeting. General consensus is that (a) an individualized approach to immunosuppression is needed; (b) biopsy findings are of importance in patient and allograft monitoring and (c) pathologists need to have input in defining SOT. Several groups re-enforced the contribution of antibodies to liver allograft damage, including an inability to wean immunosuppression from recipients showing DSA and diffuse C4d+ staining. Newer technologies, such as mRNA arrays and multiplex tissue staining/digital slide imaging, were introduced as means to optimize biopsy analysis with the
following goals: (a) better understand and classify immunologic mechanisms of tissue injury and allograft acceptance; and (b) predict which patients might be successfully weaned from immunosuppression. Upcoming goals of the Banff liver group for 2013 include a better understanding of (1) spectrum of ABMR with consensus guidelines for interpreting C4d stains; (2) SOT; (3) donor organ biopsy evaluation and (4) continued integration of newer technologies.

**Pancreas allografts**—The pancreas group recently published consensus guidelines for the diagnosis of ABMR (38) emphasizing the need for clinicopathological integration for the diagnosis of ABMR in pancreas allografts similar to renal allografts, i.e. DSA, MI and C4d in interacinar capillaries. The pancreas session at the 2011 Banff meeting focused on practical and reproducibility issues for the interpretation of C4d staining, the differential diagnostic features of TCMR and ABMR, and histological and clinical features of recurrent autoimmune diabetes mellitus type 1. Also the systematic use of surveillance and for cause pancreas allograft biopsies and practical difficulties for biopsy graft accessibility were reviewed. Experiences with retroperitoneal enteric-drained pancreas transplants were discussed against enteroscopic biopsies of the duodenal allografts as surrogate samples to detect pancreatic allograft rejection. The group identified four priorities for future studies (1) to determine the impact of protocol biopsies in clinical practice, (2) assess the equality of duodenal cuff versus pancreas parenchyma biopsies, (3) to determine the incidence of islet pathology, (4) to assess and improve if necessary, the reproducibility of the updated Banff grading schema.

**Lung allografts**—This session focused on reviewing available immunology, serology and pathology data of ABMR in lung allografts and their clinical correlates. Significant gaps in the understanding of ABMR-related pathologic changes in lungs were identified. The group agreed to initiate a study under the auspices of Banff in an attempt to correlate experiences from multiple large lung transplant centers. The study will compile cases of patients who had biopsies and de novo DSA with the aim to identify the most pertinent and reproducible histological lesions that are clinically most relevant. Goal is to develop internationally acceptable recommendations for the pathologic diagnosis of ABMR in lung allografts. In addition to ABMR the relevance of non-BOS chronic graft dysfunction, infectious complications and the role of endothelial cells in vascular pathology and subsequent graft deterioration were reviewed as significant clinical challenges in lung allograft patients.

**Vascularized composite allografts (VCA)**—The VCA session focused on an update of chronic changes and antibody-mediated findings. Experiences in human and non-human-primate models suggested ischemic changes, alloimmune injury to skin, transplant arteriopathy and superficial versus deep tissue rejection as the most relevant differential diagnosis occurring in VCA. Vascular intimal thickening, nail changes, loss of hair follicles in the context of the development of DSA and potential consecutive graft loss due to ABMR were discussed. Ultrasound bio-microscopy was identified as a monitoring tool for graft vascular changes. Vascular narrowing appears to be related with myointimal proliferation, loss of adnexa, skin atrophy, fibrosis of deep tissue, endarteritis and endothelialitis as potential long-term alloimmune-mediated changes in VCA. Thus the following priorities for future research in the VCA area were identified: validation of the current Banff VCA classification (39), interpretation of long-term changes and related biomarkers, differential diagnosis of inflammation versus rejection, ABMR, significance of myointimal proliferation.

**Heart allografts**—A major focus of the 2011 Banff meeting was the further refinement of the recently revised diagnostic criteria for ABMR in heart allografts (40). In this regard
numerous research studies were reviewed and collaborative future efforts were discussed. A
detailed report summarizing the outcome from these discussions will be published
separately.

The role of epithelium in allograft deterioration

Data regarding epithelial injury and repair processes in different types of organ transplants
were reviewed. With this it became obvious that no robust evidence is available that a
phenomenon called “Epithelial Mesenchymal Transition” (EMT) truly exists in organ
transplants. There was broad acceptance of the fact that epithelial cells in situ can change
their phenotype toward a mesenchymal one. However, no evidence was available that such a
dedifferentiated epithelial cell actually migrates across its basement membrane into the
adjacent interstitium and starts to lay down collagen. Elegant molecular, mechanistic and
imaging data were provided demonstrating that all epithelial cells in a variety of organs
(tubular by Groene and Hertig; biliary by Kirby et al.; bronchial by Fisher et al.) show a
highly stereotyped response to any kind of injury. This includes the re-expression of
embryonic and developmental pathways and with this epithelial cells assume a more
mesenchymal phenotype as a sign of dedifferentiation, which often represents a transient
state (41). The expression of the mesenchymal phenotype frequently colocalizes with
increased inflammation and matrix production in the adjacent interstitium. However there is
no convincing evidence that the source of fibrosis is the migrated, dedifferentiated epithelial
cell, but rather an adjacent, residential interstitial cell.

During an online discussion after the Banff meeting, consensus was reached that continuing
to use the term EMT would be misleading since no reliable evidence for a transition/
migration of epithelial cells across the basement membrane is available in organ transplants.
Various terms were discussed with the aim to encompass the phenomenon of epithelial
dedifferentiation during the response-to-injury and the following repair processes. However,
it also became obvious that the two processes, i.e. dedifferentiation and injury–repair, are
not inevitably interconnected and still ill-defined. Therefore, the development of a new
consensus term was postponed to future Banff meetings, with expectation of further studies
of this important phenomenon.

Acknowledgments

The participants of the 11th Banff Conference gratefully acknowledge the financial support provided by the
following companies and institutions: Astellas, Novartis, Roche, Pfizer, One Lambda, CSL Behring, Transpath,
Alexion, Aperio, Philips, Omnyx, University of Alberta, National Kidney Foundation and Renal Pathology Society.

Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABMR</td>
<td>antibody-mediated rejection</td>
</tr>
<tr>
<td>BWG</td>
<td>Banff Working Group</td>
</tr>
<tr>
<td>CXM+</td>
<td>positive cross-match</td>
</tr>
<tr>
<td>CNI</td>
<td>calcineurin inhibitor</td>
</tr>
<tr>
<td>DSA</td>
<td>donor-specific antibody</td>
</tr>
<tr>
<td>FDA</td>
<td>Food and Drug Administration</td>
</tr>
<tr>
<td>IFTA</td>
<td>interstitial fibrosis and tubular atrophy</td>
</tr>
<tr>
<td>MI</td>
<td>microcirculation inflammation, i.e. glomerulitis and/or capillaritis</td>
</tr>
<tr>
<td>TCMR</td>
<td>T-cell-mediated rejection</td>
</tr>
</tbody>
</table>
TG  transplant glomerulopathy  
V-Score  Banff intimal arteritis score  
VCA  vascularized composite allograft

References


Appendix

Faculty at the 2011 Banff meeting

Akalin, Enver (UK), Alexander, Graeme (USA), Anglicheau, Dany (France), Askar, Medhat, (USA), Belperio, John (USA), Boehmig, Georg (Austria), Boggi, Ugo (Italy), Bracamonte, Rika (USA), Bröcker, Verena (Germany), Rouard, Sophie (France), Cecka, Michael (USA), Cendales, Linda (USA), Chang, Anthony (USA), Chelmonski, Adam (Poland), Colvin, Obert B. (USA), Cornell, Lynn (USA), Demetris, Anthony Jake (USA), Drachenberg, Cinthia B. (USA), Duong van Huyen, Jean Paul (France), Einecke, Gunilla (Germany), Farver, Carol (USA), Farris, Alton B. (USA), Fedrigo, Marny (Italy), Feng, Sandy (USA), Fisher, Andrew (UK), Gebel, Howard (USA), Gloor, James (USA), Glotz, Denis (France), Gröne, Hermann-Josef (Germany), Haas, Mark (USA), Hachem, Ramsey (USA), Haga, Hironori (Japan), Halloran, Philip (Canada), Hautz, Theresa (Austria), Hertig, Alexandre (France), Hidalgo, Luis (Canada), Hill, Gary (France), Hübscher, Stefan (UK), Isse, Kumiko (USA), Iversen, Martin (Denmark), Johnson, Maryl (USA), Jordan, Stanley C. (USA), Kanitakis, Jean (France), Kaufman, Christina (USA), Kim, Dae Un (USA), Kirby, John Andrew (UK), Koshiiba, Takaaki (Japan), Kraus, Edward (USA), Lefaucheur, Carmen (France), Leuvenink, Henri (The Netherlands), Liapis, Helen (USA), Loupy, Alexandre (France), Mannon, Roslyn B. (USA), Margreiter, Christian (Austria), Marisa Crespo-Leiro (Spain), Mengel, Michael (Canada), Montgomery, Bob (USA), Mundinger, Gerhard (USA), Musat, Alexandru (USA), Nankivell, Brian (Australia), Nickeleit, Volker (USA), Pallet, Nicolas (France), Papadimitriou, John (USA), Park, Walter (USA), Racusen, Lorraine (USA), Randhawa, Parmjeet (USA), Rangel, Erika (Brazil), Reeve, Jeff (Canada), Rodriguez, Rene (USA), Rose, Marlene (UK), Roysam, Badrinath (USA), Ruiz, Phillip (USA), Rush, David (Canada), Sánchez-Fueyo, Alberto (Spain), Sebagh, Mylene (France), Séron, Daniel (Spain), Sis, Banu (Canada), Solez, Kim (Canada), Stegall, Mark (USA), Tan, Carmela D. (USA), Terasaki, Paul (USA), Thervet, Eric (France), van Huyen, Jean Paul Duong (France), Wallace, William (USA), Woodle, Steven (USA), Zachary, Andrea (USA), Zeevi, Adriana (USA).
Table 1
Scope, preliminary results and activity status of current Banff Working Groups

<table>
<thead>
<tr>
<th>Banff Working Group (BWG)</th>
<th>Scope</th>
<th>Preliminary results</th>
<th>Current activity status</th>
<th>Lead and contact person</th>
</tr>
</thead>
<tbody>
<tr>
<td>C4d – Banff initiative for quality assurance in transplantation (BIFQUIT)</td>
<td>Assessment of interlaboratory and interobserver reproducibility of C4d immunohistochemistry in paraffin-embedded kidney allograft specimens</td>
<td>A fair to moderate reproducibility between laboratories and observers was observed. Also data regarding the optimal staining protocol were collected</td>
<td>Trial and data analysis completed. Manuscript in preparation</td>
<td>Michael Mengel, University of Alberta, Edmonton, Canada, Parmjeet Randhawa, University of Pittsburgh, Pittsburgh, USA</td>
</tr>
<tr>
<td>BK – Banff initiative for quality assurance in transplantation (BIFQUIT)</td>
<td>Assessment of interlaboratory and interobserver reproducibility of polyomavirus immunohistochemistry in paraffin-embedded kidney specimens</td>
<td>This multicenter trial revealed that the proposed scoring system for BK stains shows a substantial interobserver reproducibility, while the interlaboratory reproducibility is quite limited. Also data regarding the optimal staining protocol were collected</td>
<td>Trial and data analysis completed. Manuscript in preparation</td>
<td>Parmjeet Randhawa, University of Pittsburgh, Pittsburgh, USA, Michael Mengel, University of Alberta, Edmonton, Canada</td>
</tr>
<tr>
<td>Glomerular lesion BWG</td>
<td>Assessment of interobserver reproducibility and diagnostic significance of established and alternative glomerulitis and TG scoring approaches</td>
<td>A limited reproducibility of glomerulitis and acceptable reproducibility of TG scoring was observed</td>
<td>First trial and data analysis completed. Follow-up trial in preparation with the aim to define reproducible diagnostic thresholds for glomerulitis and transplant glomerulopathy</td>
<td>Mark Haas, Cedars Sinai Hospital, Los Angeles, USA, Banu Sis, University of Alberta, Edmonton, Canada</td>
</tr>
<tr>
<td>Isolated v-lesion BWG</td>
<td>Conduction of a retrospective multicenter study analyzing the clinical significance of isolated v-lesions</td>
<td>Isolated v-lesion were found to be associated with either ABMR, or TCMR, or delayed graft function, indicating that a more differentiated diagnostic and tailored therapeutic approach toward isolated v-lesion cases is warranted</td>
<td>Trial and data analysis completed. Manuscript in preparation</td>
<td>Banu Sis, University of Alberta, Edmonton, Canada, Edward Kraus, Johns Hopkins University, Baltimore, USA</td>
</tr>
<tr>
<td>Implantation biopsies BWG</td>
<td>Conduction of a retrospective multicenter study analyzing the reproducibility (including frozen versus paraffin) and predictive value of lesions in implantation biopsies</td>
<td>The generated preliminary trial data as well as those available in the literature do not justify discarding a procured kidney solely based on histological findings. The sample size for the trial was small and thus a follow-up trial will be conducted</td>
<td>First trial and data analysis completed. Follow-up trial in preparation</td>
<td>Helen Liapis, Gerge Washington University, St. Louis, USA, Parmjeet Randhawa, University of Pittsburgh, Pittsburgh, USA</td>
</tr>
<tr>
<td>Polyomavirus BWG</td>
<td>Conduction of a retrospective multicenter study analyzing the reproducibility and clinical significance of a provisional PVN scoring schema proposed at the 2009 Banff meeting</td>
<td>Acceptable reproducibility of the in 2009 proposed grading schema was seen. Group discussion of the clinical significance did not generated consensus and thus the proposal was not integrated into the classification at the 2011 Banff meeting</td>
<td>First trial completed. Further data analysis underway. Potential follow-up trial under consideration</td>
<td>Volker Nickeleit, University of North Carolina, Chapel Hill, USA</td>
</tr>
<tr>
<td>Fibrosis BWG</td>
<td>Assessment of interobserver reproducibility and clinical significance of different stains and methods for the visual fibrosis assessment using the trichrome stain with computer and immunohistochemistry-</td>
<td>A good correlation between visual fibrosis assessment completed. Follow-up trial for testing refined criteria for the assessment of</td>
<td>First trial and data analysis completed. Follow-up trial for testing refined criteria for the assessment of</td>
<td>Alton B Farris, Emory University, Atlanta, USA</td>
</tr>
<tr>
<td>Banff Working Group (BWG)</td>
<td>Scope</td>
<td>Preliminary results</td>
<td>Current activity status</td>
<td>Lead and contact person</td>
</tr>
<tr>
<td>--------------------------</td>
<td>-------</td>
<td>---------------------</td>
<td>------------------------</td>
<td>------------------------</td>
</tr>
<tr>
<td>C4d-negative ABMR BWG</td>
<td>Established at the 2011 Banff meeting with the aim to define diagnostic criteria for C4d-negative ABMR</td>
<td>None yet</td>
<td>During an online discussion after the 2011 meeting available data were reviewed and currently efforts are underway for designing respective multicenter studies with the aim to define evidence-based diagnostic criteria for C4d-negative ABMR</td>
<td>Mark Haas, Cedars Sinai Hospital, Los Angeles, USA Banu Sis, University of Alberta, Edmonton, Canada Alexandre Loupy, Hôpital Européen Georges Pompidou, Paris, France</td>
</tr>
</tbody>
</table>